Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study
<p><strong>Background</strong> Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of age was introduced in Kenya in January, 2011, accompanied by a catch-up campaign in Kilifi County for children aged younger than 5 years. Coverage with at least two...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2019
|
| _version_ | 1797104628607746048 |
|---|---|
| author | Hammitt, LL Etyang, AO Morpeth, SC Ojal, J Mutuku, A Mturi, N Moisi, JC Adetifa, IM Karani, A Akech, DO Otiende, M Bwanaali, T Wafula, J Mataza, C Mumbo, E Tabu, C Knoll, MD Bauni, E Marsh, K Williams, TN Kamau, T Sharif, SK Levine, OS Scott, JAG |
| author_facet | Hammitt, LL Etyang, AO Morpeth, SC Ojal, J Mutuku, A Mturi, N Moisi, JC Adetifa, IM Karani, A Akech, DO Otiende, M Bwanaali, T Wafula, J Mataza, C Mumbo, E Tabu, C Knoll, MD Bauni, E Marsh, K Williams, TN Kamau, T Sharif, SK Levine, OS Scott, JAG |
| author_sort | Hammitt, LL |
| collection | OXFORD |
| description | <p><strong>Background</strong> Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of age was introduced in Kenya in January, 2011, accompanied by a catch-up campaign in Kilifi County for children aged younger than 5 years. Coverage with at least two PCV10 doses in children aged 2–11 months was 80% in 2011 and 84% in 2016; coverage with at least one dose in children aged 12–59 months was 66% in 2011 and 87% in 2016. We aimed to assess PCV10 effect against nasopharyngeal carriage and invasive pneumococcal disease (IPD) in children and adults in Kilifi County.</p> <p><strong>Methods</strong> This study was done at the KEMRI-Wellcome Trust Research Programme among residents of the Kilifi Health and Demographic Surveillance System, a rural community on the Kenyan coast covering an area of 891 km<sup>2</sup>. We linked clinical and microbiological surveillance for IPD among admissions of all ages at Kilifi County Hospital, Kenya, which serves the community, to the Kilifi Health and Demographic Surveillance System from 1999 to 2016. We calculated the incidence rate ratio (IRR) comparing the prevaccine (Jan 1, 1999–Dec 31, 2010) and postvaccine (Jan 1, 2012–Dec 31, 2016) eras, adjusted for confounding, and reported percentage reduction in IPD as 1 minus IRR. Annual cross-sectional surveys of nasopharyngeal carriage were done from 2009 to 2016.</p> <p><strong>Findings</strong> Surveillance identified 667 cases of IPD in 3 211 403 person-years of observation. Yearly IPD incidence in children younger than 5 years reduced sharply in 2011 following vaccine introduction and remained low (PCV10-type IPD: 60·8 cases per 100 000 in the prevaccine era <em>vs</em> 3·2 per 100 000 in the postvaccine era [adjusted IRR 0·08, 95% CI 0·03–0·22]; IPD caused by any serotype: 81·6 per 100 000 <em>vs</em> 15·3 per 100 000 [0·32, 0·17–0·60]). PCV10-type IPD also declined in the post-vaccination era in unvaccinated age groups (<2 months [no cases in the postvaccine era], 5–14 years [adjusted IRR 0·26, 95% CI 0·11–0·59], and ≥15 years [0·19, 0·07–0·51]). Incidence of non-PCV10-type IPD did not differ between eras. In children younger than 5 years, PCV10-type carriage declined between eras (age-standardised adjusted prevalence ratio 0·26, 95% CI 0·19–0·35) and non-PCV10-type carriage increased (1·71, 1·47–1·99).</p> <p><strong>Interpretation</strong> Introduction of PCV10 in Kenya, accompanied by a catch-up campaign, resulted in a substantial reduction in PCV10-type IPD in children and adults without significant replacement disease. Although the catch-up campaign is likely to have brought forward the benefits by several years, the study suggests that routine infant PCV10 immunisation programmes will provide substantial direct and indirect protection in low-income settings in tropical Africa.</p> |
| first_indexed | 2024-03-07T06:36:24Z |
| format | Journal article |
| id | oxford-uuid:f7ce8a4e-07a9-40fb-baef-6945c02c94a3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:36:24Z |
| publishDate | 2019 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:f7ce8a4e-07a9-40fb-baef-6945c02c94a32022-03-27T12:45:23ZEffect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f7ce8a4e-07a9-40fb-baef-6945c02c94a3EnglishSymplectic Elements at OxfordElsevier2019Hammitt, LLEtyang, AOMorpeth, SCOjal, JMutuku, AMturi, NMoisi, JCAdetifa, IMKarani, AAkech, DOOtiende, MBwanaali, TWafula, JMataza, CMumbo, ETabu, CKnoll, MDBauni, EMarsh, KWilliams, TNKamau, TSharif, SKLevine, OSScott, JAG<p><strong>Background</strong> Ten-valent pneumococcal conjugate vaccine (PCV10), delivered at 6, 10, and 14 weeks of age was introduced in Kenya in January, 2011, accompanied by a catch-up campaign in Kilifi County for children aged younger than 5 years. Coverage with at least two PCV10 doses in children aged 2–11 months was 80% in 2011 and 84% in 2016; coverage with at least one dose in children aged 12–59 months was 66% in 2011 and 87% in 2016. We aimed to assess PCV10 effect against nasopharyngeal carriage and invasive pneumococcal disease (IPD) in children and adults in Kilifi County.</p> <p><strong>Methods</strong> This study was done at the KEMRI-Wellcome Trust Research Programme among residents of the Kilifi Health and Demographic Surveillance System, a rural community on the Kenyan coast covering an area of 891 km<sup>2</sup>. We linked clinical and microbiological surveillance for IPD among admissions of all ages at Kilifi County Hospital, Kenya, which serves the community, to the Kilifi Health and Demographic Surveillance System from 1999 to 2016. We calculated the incidence rate ratio (IRR) comparing the prevaccine (Jan 1, 1999–Dec 31, 2010) and postvaccine (Jan 1, 2012–Dec 31, 2016) eras, adjusted for confounding, and reported percentage reduction in IPD as 1 minus IRR. Annual cross-sectional surveys of nasopharyngeal carriage were done from 2009 to 2016.</p> <p><strong>Findings</strong> Surveillance identified 667 cases of IPD in 3 211 403 person-years of observation. Yearly IPD incidence in children younger than 5 years reduced sharply in 2011 following vaccine introduction and remained low (PCV10-type IPD: 60·8 cases per 100 000 in the prevaccine era <em>vs</em> 3·2 per 100 000 in the postvaccine era [adjusted IRR 0·08, 95% CI 0·03–0·22]; IPD caused by any serotype: 81·6 per 100 000 <em>vs</em> 15·3 per 100 000 [0·32, 0·17–0·60]). PCV10-type IPD also declined in the post-vaccination era in unvaccinated age groups (<2 months [no cases in the postvaccine era], 5–14 years [adjusted IRR 0·26, 95% CI 0·11–0·59], and ≥15 years [0·19, 0·07–0·51]). Incidence of non-PCV10-type IPD did not differ between eras. In children younger than 5 years, PCV10-type carriage declined between eras (age-standardised adjusted prevalence ratio 0·26, 95% CI 0·19–0·35) and non-PCV10-type carriage increased (1·71, 1·47–1·99).</p> <p><strong>Interpretation</strong> Introduction of PCV10 in Kenya, accompanied by a catch-up campaign, resulted in a substantial reduction in PCV10-type IPD in children and adults without significant replacement disease. Although the catch-up campaign is likely to have brought forward the benefits by several years, the study suggests that routine infant PCV10 immunisation programmes will provide substantial direct and indirect protection in low-income settings in tropical Africa.</p> |
| spellingShingle | Hammitt, LL Etyang, AO Morpeth, SC Ojal, J Mutuku, A Mturi, N Moisi, JC Adetifa, IM Karani, A Akech, DO Otiende, M Bwanaali, T Wafula, J Mataza, C Mumbo, E Tabu, C Knoll, MD Bauni, E Marsh, K Williams, TN Kamau, T Sharif, SK Levine, OS Scott, JAG Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study |
| title | Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study |
| title_full | Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study |
| title_fullStr | Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study |
| title_full_unstemmed | Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study |
| title_short | Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study |
| title_sort | effect of ten valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in kenya a longitudinal surveillance study |
| work_keys_str_mv | AT hammittll effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT etyangao effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT morpethsc effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT ojalj effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT mutukua effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT mturin effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT moisijc effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT adetifaim effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT karania effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT akechdo effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT otiendem effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT bwanaalit effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT wafulaj effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT matazac effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT mumboe effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT tabuc effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT knollmd effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT baunie effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT marshk effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT williamstn effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT kamaut effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT sharifsk effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT levineos effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy AT scottjag effectoftenvalentpneumococcalconjugatevaccineoninvasivepneumococcaldiseaseandnasopharyngealcarriageinkenyaalongitudinalsurveillancestudy |